UNSPSC 51314391: Ambroxol/dextromethorphan

This classification denotes a combination drug composed of two constituents: a mucolytic and an opioid receptor agonist and opioid, as more fully appears.

The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90].

UNSPSC 51314391 Ambroxol/dextromethorphan is a Commodity code that in practice encompasses a much broader range of pharmaceutical products and systems than its nominal name suggests. Recent state and local opportunities tagged under this code show procurement of naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products supplied through authorized wholesalers, and exploratory direct-to-manufacturer prescription programs. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance or MMCAP, serving Minnesota, Oregon, and other participating jurisdictions). Procurement mechanisms range from competitive sealed bids for specific unit quantities to Request for Proposal (RFP) formats establishing standing contracts with multiple vendors, and Request for Information (RFI) processes to test vendor capabilities before formal solicitation.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County's IFB 60459723LAS, posted June 30, 2026 with a July 26, 2023 response date, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, pricing on a fixed-fee basis with an initial two-year term and one-year renewal option. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathers vendor information on direct-to-manufacturer prescription fulfillment models and strategies for self-insured employers and government health plans. MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with a March 26, 2026 proposal due date, establishes multi-year standing contracts effective July 1, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), maintain cGMP and DSCSA compliance, and accept a 3 percent administrative fee on all contract purchases. All three opportunities include standard state and local compliance requirements such as E-Verify, insurance coverage, drug-free workplace certification, and workers' compensation.